These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31527206)

  • 1. Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
    Reynolds SB; Maghavani DP; Hashmi H
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31527206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acquired factor X deficiency developed four years after autologous transplantation in a patient with multiple myeloma associated with systemic AL amyloidosis].
    Takemura T; Fukatsu Y; Nagata Y; Asahina A; Yokota D; Hirano I; Yagyu T; Ono T; Katsumi A; Ohnishi K
    Rinsho Ketsueki; 2014 May; 55(5):558-62. PubMed ID: 24881922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired factor X deficiency in a multiple myeloma without amyloidosis: a case report.
    Coussee A; Alliet G; Hervent AS; Vynckier L; Emmerechts J; Van Hecke S; Persijn L
    Acta Clin Belg; 2023 Dec; 78(6):524-528. PubMed ID: 37800976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib: A Case Report and Review of the Literature.
    Jia J; Wang H; Wu M; Zhang F; Liu X; Chen W; Liu A
    Acta Haematol; 2018; 140(1):46-50. PubMed ID: 30114681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired von Willebrand syndrome in association with multiple myeloma: remission after stem cell transplant.
    Shah CP; Delaune J; Mandernach MW
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33504531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy.
    Smith SV; Liles DK; White GC; Brecher ME
    Am J Hematol; 1998 Mar; 57(3):245-52. PubMed ID: 9495379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
    Breems DA; Sonneveld P; de Man RA; Leebeek FW
    Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial.
    Yokoyama A; Kada A; Saito AM; Sawamura M; Komeno T; Sunami K; Takezako N
    Acta Med Okayama; 2019 Dec; 73(6):547-552. PubMed ID: 31871340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
    Choufani EB; Sanchorawala V; Ernst T; Quillen K; Skinner M; Wright DG; Seldin DC
    Blood; 2001 Mar; 97(6):1885-7. PubMed ID: 11238135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful perioperative management of factor X deficiency associated with primary amyloidosis.
    Takabe K; Holman PR; Herbst KD; Glass CA; Bouvet M
    J Gastrointest Surg; 2004; 8(3):358-62. PubMed ID: 15019934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.
    Kawano Y; Hata H; Takashio S; Tsujita K; Ueda M; Matsuoka M
    Br J Haematol; 2022 Aug; 198(3):e38-e41. PubMed ID: 35524546
    [No Abstract]   [Full Text] [Related]  

  • 13. Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis.
    Enjeti AK; Walsh M; Seldon M
    Haemophilia; 2005 Sep; 11(5):535-8. PubMed ID: 16128899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
    Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
    Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term remission of acquired von Willebrand syndrome associated with multiple myeloma using bortezomib and dexamethasone therapy.
    Katagiri S; Akahane D; Amano K; Ohyashiki K
    Haemophilia; 2016 Nov; 22(6):e557-e559. PubMed ID: 27641423
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired factor X deficiency in light chain amyloidosis: a report of 2 Korean cases.
    Ma Y; Kwon EH; Lee JE; Kim K; Kim HJ; Kim SH
    Korean J Lab Med; 2011 Jul; 31(3):154-6. PubMed ID: 21779187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normalization of plasma factor X levels in amyloidosis after plasma exchange.
    Beardell FV; Varma M; Martinez J
    Am J Hematol; 1997 Jan; 54(1):68-71. PubMed ID: 8980263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
    Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
    Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.